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Poster Session I 53syndrome (HPS) early after cord blood transplantation (CBT). Al-
though both can be serious and potentially fatal, not much data have
been available regarding their mechanisms underlying them. Re-
cently, we observed a group of patients who presented relative lym-
phocytosis (LC) early after CBTbefore engraftment.We decided to
conduct a retrospective analysis of those who presented LC early af-
ter transplant to characterize clinical features and to evaluate possi-
ble relevance to abovementioned immune-mediated complications.
Patients and Definition: Patients who underwent RI-CBT at
our institute from Jan.2005 to July 2007 were retrospectively re-
viewed. LC was defined by early lymphocyte-dominant ($80%) in-
crease of WBC for at least 3 consecutive days. Lymphocyte count
must be over 200/ul at least once. Result: We observed 11 cases
who presented LC. Eight out of 11 were of donor-type and 3 of re-
cipient-type chimerism. Median onset of LC of donor cells was 8.5
(8–10) days, and the maximum number of lymphocyte was 519
(242–2828)/ul, primarily CD3-positive T cells with CD4–81 dom-
inancy (60.6(13–68.1)%). Fever and diarrhea were observed in all
patients, liver damage in 7, skin eruption in 4, and HPS in 6. Six
out of 8 experienced graft failure, whereas the remaining 2 experi-
enced severe acute GVHD, resulted in 6 early death up to 50 days
post-transplant. LC of recipient cells developed on median 13
(12–16) days post-transplant, and themaximumnumber of lympho-
cyte was 550 (280–880)/ul, in which CD4–81 cells dominated
(93.1(83.1–96.6)%). All 3 experienced graft rejection and 2 of
them were rescued by second RI-CBT, while 1 died of infection.
Conclusion: LC of either donor- or recipient-derived was sugges-
tive of high incidence of graft failure. Further analyses are currently
going on to investigate possible relevance of LC to PIR or HPS.
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HOWREALISTIC IS IT TO EXPECT A FULLY ALLELE LEVELMATCHEDDO-
NOR FROM A SEARCH THROUGH THE NMDP? A 10 YEAR, SINGLE INSTI-
TUTION EXPERIENCE
Askar, M.1, Sobecks, R.2, Kalaycio, M.2, Dean, R.2, Copelan, E.2,
Rybicki, L.3, Pohlman, B.2, Bolwell, B.2 1Transplant Center; 2Taussig
Cancer Center; 3Cleveland Clinic.
TheNationalMarrowDonor Program (NMDP) continues to ex-
pand its donor pool. Transplant outcome correlates with the degree
of HLA matching. Ideally, NMDP searches result in fully matched
donors at the allele level. The odds of finding such a donor, how-
ever, has not been widely discussed.
We performed a retrospective analysis of 517 searches to the
NMDP fromNovember, 1996 through November, 2006. Of these,
213 resulted in a transplant. This analysis is limited to the patients
that actually proceeded to transplant because of multiple potential
reasons beyond HLA matching that may have prevented patients
from receiving a transplant. Only 36 (17%) of 213 transplanted pa-
tients had donors that were fully matched at the allele level. Ninety-
four (44%) patients were mismatched at only DP. Sixty-seven
(31%) patients had a class 1, or DRB1mismatch. The median dura-
tion from the initiation from NMDP search to transplant was 5.2
months. We conclude that finding fully matched donors is still
a challenge, and highlights the need for continued recruitment
for volunteers to the NMDP registry. Indeed, a result of 17% is
likely an overestimate of the number of fully matched searches, be-
cause this analysis only included the patients who proceeded to
transplant. Additionally, 8/8 matched donors with DP mismatches
are common.
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BORTEZOMIB PLUS TACROLIMUS/METHOTREXATE FOR PROPHYLAXIS
OF ACUTE GVHD AFTER HLA MISMATCHED ALLOGENEIC NON-MYELOA-
BLATIVE TRANSPLANTATION: RESULTS OF A DOSE FINDING PHASE I
STUDY
Koreth, J.1, Kim, H.T.2, Ho, V.T.1, Cutler, C.S.1, Soiffer, R.J.1,
Antin, J.H.1, Alyea, E.P.1 1Dana Farber Cancer Institute, Boston,
MA; 2Dana Farber Cancer Institute, Boston, MA.
There is a need for better control of graft versus host disease
(GVHD) after HLA mismatched peripheral blood stem cell
(PBSC) allogeneic transplantation. Bortezomib is a small moleculeproteasome inhibitor approved for treatment of multiple myeloma.
It has immunomodulatory properties, and preclinical data indicate
utility in GVHD control after allogeneic transplantation. Here we
report the dose finding portion of a Phase I/II trial of bortezomib
(dose levels A, B, C: 1, 1.3, 1.5 mg/m2) plus tacrolimus and mini-
methotrexate for GVHD prophylaxis after HLA mismatched non
myeloablative allogeneic stem cell transplantation (NST) for pa-
tients with hematologic malignancies. Dose limiting toxicity
(DLT) by day 45 post PBSC infusion is the primary endpoint,
both acute bortezomib toxicity (e.g. neuropathy) and negative im-
pact on stem cell function (e.g. delayed neutrophil recovery or
poor donor engraftment) in the absence of disease progression. Sec-
ondary endpoints include incidence of acute and chronic GVHD.
Patients with 1–2 locus antigen/allele mismatch (HLA-A, -B, -C,
-DRB1) were eligible. Pretransplant conditioning was busulfex (0.8
mg/kg/d) and fludarabine (30 mg/m2/d) each for 4 days. GVHD
prophylaxis was bortezomib per dose level (day 11, 14, 17) plus
tacrolimus (day –3 to 1180) and mini-methotrexate (5 mg/m2 on
day 11, 13, 16, 111).
13 patients were enrolled. No neurotoxicity was noted. At dose
level A, 1 of 5 patients had a possible DLT, with poor engraftment
likely related to progression of underlying MDS/AML. At dose
level B, 0 of 3 patients had a DLT. At dose level C, 2 of 5 patients
had a DLT. One patient, with minimally treated myeloproliferative
disease failed to engraft; another patient, with CLL, experienced an
immunologic graft rejection.
Grade 2–4 aGVHD occurred in 2 of 13 patients (1 each at dose
level A and C). Chronic GVHD occurred in 3 patients, all at dose
level A, albeit with limited follow up. Disease relapse has occurred
in 5 patients (2 of whomdied), one at dose level B, and 2 each at dose
levels A and C. In summary, GVHD prophylaxis with bortezomib
1.3 mg/m2 plus tacrolimus/mini-methotrexate is convenient and
well tolerated after busulfex/fludarabine conditioning in HLA mis-
matched NST. It may have efficacy in GVHD control, and phase II
accrual is proceeding.LATE EFFECTS/QUALITY OF LIFE141
SIMILAR RISKS FOR HYPOTHYROIDISM IN MYELOABLATIVE AND RE-
DUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT
SURVIVORS
Al-Hazzouri, A., Cao, Q., Burns, L.J., Weisdorf, D.J., Majhail, N.S.
University of Minnesota, Minneapolis, MN.
Upto 15% of adult myeloablative (MA) allogeneic hematopoietic
cell transplant (HCT) survivors can develop hypothyroidism. HCT
using reduced-intensity conditioning (RIC) is associated with lower
morbidity and mortality, but the risk of hypothyroidism after RIC
HCT is not known. We conducted a retrospective cohort study
to compare the incidence of hypothyroidism after MA and RIC
HCT. Adult allogeneic HCT recipients were eligible if (1) they
had received an allogeneic HCT using a total body irradiation
(TBI) based MA or RIC regimen between 2000 and 2005, (2) sur-
vived for$1 year post-HCT, and (3) had no history of hypothyroid-
ism pre-HCT. TBI dose in MA and RIC regimens was 1320 cGy
(165 cGy twice daily 4 days) and 200 cGy (single fraction), respec-
tively. Hypothyroidism was classified as subclinical (elevated thy-
roid stimulating hormone [TSH] and normal free thyroxine
[FT4]) or overt (elevated TSH and low FT4). All patients had thy-
roid studies performed at least annually after HCT; if clinically in-
dicated, more frequent assessments were conducted at the
discretion of the treating physician. Study eligibility criteria were
met by 181 patients (MA 5 84, RIC 5 97); median follow-up was
28 (range, 12–75) months for MA and 25 (range, 12–67) months
for RIC group. MA recipients were younger (median age 37 vs.
54 years, P \ 0.01), the two groups were otherwise comparable
with respect to gender, race, HCT co-morbidity index scores, dis-
ease status, donor source and incidences of acute and chronic
GVHD. Eleven patients developed hypothyroidism (subclinical -
9, overt - 2). The 3-year cumulative incidence of hypothyroidism
was 8% (95% confidence intervals [CI], 1–14%) in MA and 5%
(95%CI, 0–11%) in RIC groups (p5 0.41). Inmultivariate analyses
that included age, gender, race, conditioning regimen intensity,
54 Poster Session IHCT co-morbidity index scores, disease status, donor source, and
acute and chronic GVHD, similar risks for developing hypothy-
roidism were observed between the two types of conditioning reg-
imens (relative risk for MA 1.6 [95% CI, 0.4–5.8] vs. RIC).
Female gender was the only factor predictive for hypothyroidism
(relative risk 4.5 [95%CI, 1.1–18.0] vs. males). In conclusion, hypo-
thyroidism is relatively infrequent in adult allogeneic HCT survi-
vors. At least in the first few years post-HCT, RIC is associated
with similar risks for hypothyroidism as MA conditioning.142
HIGH PREVALENCE OF IRON OVERLOAD IN ADULT SURVIVORS OF AL-
LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Majhail, N.S.1, DeFor, T.E.1, Kang, B.2, Paley, C.2, Lazarus, H.3,
Burns, L.J.1 1University of Minnesota, Minneapolis, MN; 2Novartis
Pharmaceuticals, East Hanover, NJ; 3Case Western Reserve University,
Cleveland, OH.
Iron overload is a well recognized complication of transfusion de-
pendent anemias. A large number of allogeneic hematopoietic cell
transplant (HCT) recipients receive red blood cell (RBC) transfu-
sions and pre-HCT serum ferritin has been reported to be an inde-
pendent predictor for early transplant related mortality. However,
the prevalence of iron overload in long-term allogeneic transplant
survivors is not known. We report a cross-sectional study of iron
overload in this population. Adult allogeneic HCT recipients
were eligible if they: (1) had survived for $12 months from their
transplant, (2) had no active infections, (3) had no active flare of
chronic graft-versus-host disease, and (4) had no contraindication
for magnetic resonance imaging (MRI) scan. Patients who con-
sented for participation were screened with serum ferritin (normal
range 10–300 ng/mL), and those with serum ferritin .1000 ng/
mL underwent R2MRI of the liver to measure liver iron concentra-
tion (LIC, normal range 0.17–1.8 mg/g dry tissue) using the Ferri-
Scan technology, a highly sensitive and specific technique for
measuring hepatic iron content (St Pierre et al, Blood 2005, 105:
855). Iron overload was defined as LIC above the normal range
(.1.8 mg/g). Forty eight patients were enrolled and were a median
of 27 (range, 12–151) months fromHCT. All were RBC transfusion
independent at the time of study enrollment. Median age was 49
(range, 24–69) years and 54% were males. The most common indi-
cations for HCT were acute leukemia (44%) and non-Hodgkin’s
lymphoma (31%). Eighteen patients had serum ferritin .1000
ng/mL (median 1516 [range, 1003–7311]); of these 17 had iron
overload on MRI (median LIC 7.5 (range, 2.8–28.3) mg/g), with
an overall prevalence rate of 35% (95% confidence intervals [CI],
22–51%). Clinically significant iron overload (LIC .5 mg/g) was
present in 11 patients (23% [95% CI, 12–37%]). LIC level on
MRI was only moderately correlated with serum ferritin level (r 5
0.49 [95% CI, 0.10–0.88]) and transferrin saturation level (r 5
0.55 [95%CI, 0.13–0.97]). In conclusion, iron overload is a frequent
late complication of allogeneicHCT. Serum ferritin is a good initial
screening test but it may not predict the level of hepatic iron content
and may not be useful by itself for identifying clinically significant
iron overload.More studies are needed to determine the natural his-
tory and treatment of iron overload in allogeneic HCT survivors.
Total Myeloablative/ Medianpatients
(N 5 48) mNon-
yeloablative URelated/
nrelated tRBC units
ransfusedMedian
ferritin Median LICFerritin
#1000
(N 5 30)
18/12 20/10 8 364 ng/mL Not done
per protocolFerritin
.1000
(N 5 18)
13/5 12/6 24 1516 ng/mL 7.5 mg/g**17/18 patients had iron overload (liver iron concentration .1.8
mg/g on liver R2 MRI).143
PRE-TRANSPLANT PULMONARY FUNCTION AND DAY 100 NON-RE-
LAPSE MORTALITY AFTER HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION
Basu, S.K.1, Liesveld, J.L.1, Trawick, D.R.2, Fernandez, D.3,
Nichols, D.1, Fisher, S.G.3 1University of Rochester, Rochester, NY;
2University of Rochester, Rochester, NY; 3University of Rochester,
Rochester, NY.
This study’s purpose was to evaluate the association between pul-
monary function, as measured by the diffusion capacity of the lung
for carbon monoxide (DLCO), before hematopoietic stem cell
transplantation (HSCT) and non-relapse mortality (NRM) at 100
days post-transplant. The rationale was that DLCO, as an early in-
dicator of lung disease or as a measure of pre-existing systemic en-
dothelial damage, might be a predictor of NRM.
Methods: This was a retrospective cohort study of all patients
undergoing their first HSCT at the University of Rochester be-
tween 1995 and 2004.NRMat 100 days (Day100NRM)was the pri-
mary outcome. DLCO, as percent predicted, corrected for
hemoglobin, was the main independent variable. The chi-square
test, Mantel-Haenszel test of trend, and analysis of variance were
used for categorical, ordinal, and continuous variables respectively
in bivariate analyses. Logistic regression was used for multivariate
analysis. Results: Data regarding DLCO, mortality, and patient
characteristics were available from 677 (95%) patients. By 100
days, 59 subjects died without having a relapse. Day100NRM was
8.5% (95% confidence interval: 6.4, 10.8%). Pulmonary complica-
tions (27%), graft-versus-host disease (15%), and multi-organ fail-
ure (14%) were the most frequent causes of Day100NRM. On
crude analysis, using DLCO in quartiles, there was a statistically
significant association (chi-square p 5 0.0179) and dose response
relationship (trend test p 5 0.0023) between DLCO and
Day100NRM. Of multiple variables analyzed, only race, smoking
status, diagnosis, body mass index, forced expiratory volume at
one second, forced vital capacity, serum alkaline phosphatase, and
serum albumin, had a statistically significant association with
DLCO and were included in multivariate testing. In the final mul-
tivariate model, low DLCO, low serum albumin, and type of cancer
diagnosis remained significantly associated withDay100NRM.The
odds ratio for DLCO was 1.442 (95% confidence interval: 1.103,
1.885), using DLCO in quartiles as an ordinal variable. Patients
in the lowest quartile of DLCOwere almost three-times (odds ratio
5 2.99) as likely as patients in the highest quartile of DLCO to ex-
perience Day100NRM. Conclusions: There was a statistically sig-
nificant association and a dose-response relationship between pre-
transplant DLCO and Day100NRM. These results suggest that
the DLCO may be helpful at the time of the pre-transplant evalua-
tion in predicting risk of Day100NRM.144
FREQUENCY OF ABNORMAL FINDINGS DETECTED BY COMPREHENSIVE
EVALUATION AT ONE YEAR AFTER HEMATOPOIETIC CELL TRANSPLAN-
TATION
Lee, S.J.1, Seaborn, T.2, Massey, S.2, Mao, F.J.2, Luu, N.2,
Moravec, C.1, Carpenter, P.A.1, Martin, P.J.1, Flowers, M.E.D.1
1Fred Hutchinson Cancer Research Center, Seattle, WA; 2University
of Washington, Seattle, WA.
Medical records of 118 adults (88% of eligible patients alive with-
out relapse) who returned for evaluation at one year after allogeneic
hematopoietic cell transplantation (HCT) in 2005 were reviewed in
order to document the frequency of abnormal findings and to assess
the value of routine long-term follow-up (LTFU) assessments after
HCT.Most (n5 102, 86%) spent 2–3 days in Seattle for testing and
consultation, while 16 (14%) brought results of diagnostic testing
performed elsewhere. The cohort included 69 (58%) men and 49
women (42%), 47 (40%) who received reduced intensity condition-
ing, 62 (53%) with unrelated donors, 105 (89%) who received
growth-factor mobilized blood cells, and 18 (15%) who had second
transplants. Sixteen additional patients were alive at 1 year without
known recurrent malignancy who did not return for evaluation.
There were no statistically significant differences in the age, gender,
